Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study

Irene M. Shui,1 Xiao Qiao Liu,2 Qing Zhao,1 Seung Tae Kim,3 Yuan Sun,1 Jennifer H. Yearley,1 Tasmiah Choudhury,1 Andrea L. Webber,1 Clemens Krepler,1 Razvan Cristescu,1 Jeeyun Lee3

ABSTRACT

Background Immunotherapies targeting programmed cell death-1 (PD-1) and its ligands have improved clinical outcomes for advanced melanoma. However, many tumors exhibit primary resistance or acquire secondary resistance after an initial positive response. The mechanisms of resistance are not well understood, and no validated predictive biomarkers are available. This exploratory study aimed to characterize baseline differences and molecular changes arising during treatment in acral and mucosal melanomas that exhibited primary or secondary resistance to anti-PD-1 monotherapy.

Methods This was an observational retrospective study of 124 patients who had been treated for metastatic acral or mucosal melanoma with anti-PD-1 monotherapy. Tumor samples were collected at baseline (all patients) and post-treatment (resistant tumors only) and were assayed by immunohistochemistry, whole-exome sequencing, and RNA sequencing.

Results At baseline, more non-progression than resistant tumors exhibited expression of PD-L1, immune cell infiltration, and high tumor mutational burden (TMB); baseline PD-L1 expression was also more common in secondary-resistant than in primary-resistant tumors as well as in late versus early-secondary-resistant tumors. Non-progression tumors also had higher median baseline expression of an 18-gene T cell-influenced gene expression profile (Tcell_GEP). Among resistant tumors, the proportion of PD-L1-positive melanomas and the expression of the Tcell_GEP mRNA signature increased during treatment, while the expression of mRNA signatures related to WNT and INFA1 signaling decreased. There was evidence for greater changes from baseline in secondary-resistant versus primary-resistant tumors for some markers, including expression of RAS-related and WNT-related mRNA signatures and density of CD11c+ and FOXP3+ T cells. Greater changes in CD11c+ cell density were observed in early compared with late secondary-resistant tumors.

Conclusions Our findings suggest that Tcell_GEP and PD-L1 expression, TMB, immune cell infiltration, and RAS and WNT signaling warrant further investigation as potential mechanisms and/or biomarkers of anti-PD-1 therapy resistance in acral and mucosal melanomas. Confirmation of these findings in larger populations is needed.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Immunotherapies are a common treatment option for all histological subtypes of advanced melanoma. However, many melanomas fail to respond to anti-programmed cell death-1 (PD-1) therapy, indicating primary resistance, and a subset of initial responders subsequently acquire secondary resistance, as indicated by disease progression during treatment. The molecular mechanisms of resistance to anti-PD-1 therapy are not yet fully understood.

WHAT THIS STUDY ADDS

⇒ This study reports initial evidence for several baseline and treatment-associated characteristics of acral and mucosal melanomas, including markers of T-cell activity and RAS and WNT signaling, that may inform our understanding of resistance to anti-PD-1 monotherapy.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

⇒ The correlations reported herein should be considered for hypothesis-testing studies to determine their direct relevance to resistance mechanisms, which may inform rational combination therapies to improve immunotherapy efficacy.

BACKGROUND

Melanomas are increasingly common cancers.1–3 The most common form of the disease in white populations is cutaneous superficial spreading melanoma, while acral lentiginous and mucosal melanomas predominate in Asian populations.4–6 Cutaneous superficial spreading melanomas generally have a high tumor mutational burden (TMB) and mutational signatures characteristic of ultraviolet (UV) radiation damage.7,8 In contrast, acral and mucosal melanomas typically occur in sun-protected areas of the body and generally have a lower TMB, as well as other molecular differences.9–11 Both forms
are typically diagnosed at a later stage than cutaneous superficial spreading melanoma, with mucosal melanomas in particular being more likely to be metastatic at the time of diagnosis; there is also evidence for worse overall clinical outcomes, independent of stage.6,12 13 Despite these biological and clinical differences, current systemic treatments are similar for all forms of melanoma. Therapies directed against anticytotoxic T lymphocyte-associated antigen-4 (CTLA-4) or specific B-raf proto-oncogene serine/threonine kinase (BRAF) mutations have improved treatment options for some individuals but eventually fail for most patients.14 More recently, nivolumab and pembrolizumab were approved as first-line therapies for advanced melanoma. These drugs block the checkpoint inhibitor programmed cell death-1 (PD-1) and its ligands (PD-L1 and PD-L2) and have improved clinical outcomes compared with other options, with a better safety profile.15–22 However, many melanomas fail to respond to anti-PD-1 therapy, indicating primary resistance, and a subset of initial responders subsequently acquire secondary resistance, as indicated by disease progression during treatment.15 17 19–21 23–25

The molecular mechanisms of resistance to anti-PD-1 therapy are not yet fully understood but may be related to inhibition of T-cell activity, since greater infiltration of lymphocytes into primary melanomas is associated with better outcomes and the presence of CD8+ T cells at melanoma tumor margins has been suggested to predict response to anti-PD-1 therapy.26–28 Mutations or expression changes in beta-2-microglobulin, BRAF, phosphatase and tensin (PTEN) homolog, and interferon gamma (IFNG) signaling also potentially contribute to resistance via their effects on T-cell infiltration and antigen presentation.29 30 Gene expression signatures suggestive of a T cell-inflamed tumor microenvironment (TME), as well as signatures related to WNT and PTEN signaling, may also play a role.20 30–32 A study of four secondary-resistant melanoma samples suggested an association between resistance and alterations in interferon signaling and antigen presentation pathways;25 a similar study of four non-small cell lung cancers identified the emergence of mutations during nivolumab treatment that may affect neoantigen presentation.26 Finally, an analysis of 68 paired advanced melanoma samples identified signatures of T-cell infiltration and IFNG signaling that may be associated with response and resistance to nivolumab therapy.14

The work described earlier was conducted primarily in cutaneous superficial spreading melanomas. Among the few relatively small studies assessing immune checkpoint inhibitor therapy in patients with acral or mucosal melanoma, most reported improved prognosis compared with other therapeutic options, but some reported that the benefits were not as great as for patients with superficial spreading melanoma.33–40 Acral and mucosal melanomas may be less responsive to immunotherapy due to lower TMB compared with UV-driven forms of the disease.7 41 Specific clinical guidelines for the treatment of these tumors are needed, as are predictive biomarkers for primary and secondary resistance to anti-PD-1 therapy, to guide treatment selection and the development of the next generation of therapies and drug combinations.

The objectives of the current exploratory study were to compare the baseline molecular profiles of non-progression and resistant tumors, as well as pretreatment and post-treatment samples from resistant tumors, to identify changes in the profiles of biomarkers related to T-cell function, TMB and other phenotypes of interest. Further comparisons between primary-resistant and secondary-resistant tumors, and between tumors displaying early and late secondary resistance, were included for both objectives.

**METHODS**

**Study design**

This retrospective, observational, exploratory study was designed to generate hypotheses for future biomarker discovery and validation research.

**Study sample**

The study population comprised adults (≥18 years of age at diagnosis) with histologically confirmed metastatic acral or mucosal melanoma, or metastatic tumor of unknown primary origin with the clinical appearance of mucosal melanoma. Patients had initiated treatment with an anti-PD-1 monotherapy (pembrolizumab or nivolumab) under routine care as first-line or second-line therapy at the Samsung Medical Center in Seoul, South Korea, between January 2015 and June 2019, with ≥3 months of follow-up after treatment.

Demographic and clinical data were obtained from electronic medical records. BRAF, KIT proto-oncogene, receptor tyrosine kinase (KIT), and NRAS proto-oncogene, GTPase (NRAS) gene status were determined as part of routine clinical care using the Oncomine assay (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Patients had available archived formalin-fixed, paraffin-embedded tumor tissue (FFPET) specimens at baseline (within 1 year prior to the start of anti-PD-1 treatment if possible, with no other treatment interventions during that time) and no history of previous anti-PD-1 therapy. Most patients with resistant tumors also had available FFPET specimens taken at the time of or after the first observation of resistance (four patients had on-treatment specimens taken prior to onset of resistance). Exclusion criteria were treatment with anti-PD-1 therapy in combination with any other agent; concurrent malignancy, or history of another malignancy, at the time anti-PD-1 therapy began (exceptions were made for patients who had been disease-free for ≥3 years prior to melanoma diagnosis); history of HIV infection or other immunodeficiency; or history of systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of anti-PD-1 therapy.

Three groups of patients were selected: (1) those with primary resistance to anti-PD-1 monotherapy, (2) those with late...
with secondary resistance to anti-PD-1 monotherapy, and (3) those who responded to therapy and did not progress during the course of the study. Resistance status was determined based on best overall response (BOR), as measured by Response Evaluation Criteria in Solid Tumors V.1.1. The anti-PD-1 therapy non-progression group were those who had received anti-PD-1 monotherapy for ≥90 days and achieved partial response (PR) or complete response (CR) without subsequent progression during the study follow-up period. Primary resistance was initially defined as BOR of progressive disease (PD), or of CR, PR, or stable disease (SD) for <90 days before an observation of PD. Secondary resistance was initially defined as BOR of CR, PR, or SD for ≥90 days, but with subsequent evidence of PD, excluding pseudo-progression. This latter group was further subdivided into ‘early’ (progression <1 year after BOR) or ‘late’ (progression ≥1 year after BOR) development of resistance.

### Table 1 Patient group definitions and sample sizes

| Definition  | Total patients | Non-progressors* | Patients with resistant tumors |
|-------------|----------------|------------------|-------------------------------|
|             |                |                  | Total | Primary† | Secondary‡ |
| Original    | 124            | 14               | 110   | 61       | 49         |
| SITC§       | 122            | 14               | 108   | 76       | 32         |

During the study period, SITC’s resistance task force published new recommendations for defining primary and secondary (acquired) resistance to anti-PD-1 therapy. The original study criteria defined primary resistance as patients with a BOR of PD, or of CR, PR, or SD for <90 days before PD occurred. The SITC guidelines define primary resistance as patients with a BOR of PD, a BOR of CR, PR, or SD for <180 days before PD, and/or who progressed on treatment or within 12 weeks of stopping treatment. The SITC guidelines define secondary (acquired) resistance as patients with a BOR of CR, PR, or SD for ≥90 days before PD. The SITC guidelines define secondary (acquired) resistance as patients with CR, PR, or SD for ≥180 days who subsequently experienced PD while on treatment, within 12 weeks of stopping treatment, or after rechallenge. Secondary resistance under the original definition was further subdivided into ‘early’ (progression <1 year after BOR) or ‘late’ (progression ≥1 year after BOR) development of resistance.

*Non-progressors were defined as patients who received anti-PD-1 monotherapy treatment for ≥90 days and had PR or CR without subsequent progression during the entire study period.
†The original study criteria defined primary resistance as patients with a BOR of PD, or of CR, PR, or SD for <90 days before PD occurred.
‡The original study criteria defined secondary (acquired) resistance as patients with a BOR of CR, PR, or SD for ≥90 days before PD. The SITC guidelines define secondary (acquired) resistance as patients with CR, PR, or SD for ≥180 days who subsequently experienced PD while on treatment, within 12 weeks of stopping treatment, or after rechallenge. Secondary resistance under the original definition was further subdivided into ‘early’ (progression <1 year after BOR) or ‘late’ (progression ≥1 year after BOR) development of resistance.
§Data on whether patients progressed on treatment or within 12 weeks of stopping treatment were missing for two patients, who were therefore excluded from analyses reported by SITC definition.

The immunohistochemistry (IHC) assays for PD-L1 were performed at the Samsung Medical Center. Tumor PD-L1 expression was measured on a Dako Autostainer Link 48 system (Agilent Technologies, Santa Clara, California, USA) using the Dako PD-L1 IHC 22C3 pharmDx kit with the EnVision FLEX visualization system (Agilent Technologies). A qualified pathologist performed MEL score categorization; a MEL score of ≥2 (ie, ≥1% membrane staining in tumor and tumor-associated immune cells) was considered positive. The IHC assays for CD8, CD11c, and FOXP3 status in regulatory T cells were performed at the Research Laboratories of Merck & Co. (South San Francisco, California, USA). Triplex staining was conducted on a Bond RX stainer (Leica Biosystems, Buffalo Grove, Illinois, USA) using tyramide signal amplification (TSA) amplification-based Opal multiplexing reagents (Akoya Biosciences, Marlborough, Massachusetts, USA). Each primary antibody (anti-FOXP3 clone 236A/E7; Abcam, Boston, Massachusetts, USA; anti-CD8 clone C8/144B, Agilent Technologies; anti-CD11c clone 5D11, Leica Biosystems) was incubated for 60 min, followed by application of Opal polymer horseradish peroxidase (HRP) secondary antibody and TSA-conjugated Opal fluorophore (Akoya Biosciences). Binding of anti-FOXP3 antibody was detected using Opal 520, anti-CD8 using Opal 570, and anti-CD11c using Opal 690. Antibody stripping was performed using ERI buffer (Leica Biosystems) after each staining cycle. Nuclei were detected using Spectral DAPI (Akoya Biosciences). Stained slides were scanned using the Vectra Polaris Imaging System (Akoya Biosciences) at ≥20 magnification. Image tiles were deconvoluted using inForm software (Akoya Biosciences) and stitched into whole slide images using Halo software (Indica Labs, Albuquerque, New Mexico, USA). The numbers of positive cells per square millimetre (density) were calculated for each analyte. All staining, thresholding, and quantitation were reviewed by a qualified pathologist.
Extraction of DNA and RNA for whole-exome sequencing (WES) and RNA sequencing (RNA-Seq) assays was performed by Almac Group (Souderton, Pennsylvania, USA). Samples underwent pathology review and microdissection to identify and enrich tumor content.

DNA was extracted using the QI Amp® FF PET® DNA extraction kit (QIAGEN, Hilden, Germany). The WES assays were performed by NeoGenomics Laboratories (Fort Myers, Florida, USA). Five randomly selected patient blood samples were used to calibrate the WES assays. Libraries were prepared using the SureSelectXT LibraryPrep Kit and SureSelectXT V.5 target enrichment kit (Agilent Technologies). Sequencing was performed using the HiSeq 4000 platform (2×100 bp; Illumina, San Diego, California, USA). Sequencing reads were aligned to the human genome reference sequence (GRCh37-hg19) using the Burrows-Wheeler Alignment (BWA) maximal exact matches (MEM; BWA-MEM) algorithm (V.1.114) and Genome Analysis Toolkit (V.2) to generate analysis-ready BAM files.\(^{45-46}\) TMB was defined as the count of somatic non-synonymous mutations per exome and was calculated using MuTect V.1, Variant Effect Predictor, and PureCN V.1.6.3.\(^{47-50}\) The threshold of 175 mutations per exome for TMB-high versus TMB-low corresponds to the US Food and Drug Administration-approved clinical cutoff for TMB-high of 10 mutations/Mb using the FoundationOne CDx assay.\(^{51}\)

RNA extraction was performed using the FF PET® RNA Isolation Kit (Roche, Basel, Switzerland). The RNA-Seq assays were performed by the Almac Group. RNA-Seq libraries were prepared using the Illumina TruSeq RNA Exome protocol. All sequencing was performed on the NovaSeq 6000 (Illumina) with 2×51 bp read length. FASTQ files were generated and sequencing reads aligned to human GRCh37/hg19 using the Omicsoft sequence aligner.\(^{52}\) Gene expression levels were quantified by upper quantile normalized fragments per kilobase of transcript per million mapped reads (\(\log_2(q_n)\)).

A T cell-inflamed TME gene expression signature (TcellinfGEP) score has been previously derived across several solid tumors.\(^{53}\) It comprises the following 18 mRNAs related to antigen presentation, chemokine expression, cytolytic activity, and adaptive immune resistance: CCL5, CXCL9, CXCR6, HLA-DQA1, HLA-DRB1, HLA-E, IDO1, LG3, NKG7, PD1D1L2G (PD-L2), PSMB10, STAT1, and TIGIT. TcellinfGEP scores were calculated as a weighted sum of normalized expression values for the 18 genes, as described previously.\(^{53}\) Twelve additional RNA expression signatures comprising consensus gene sets representative of key tumor biology and microenvironment elements were derived as previously described.\(^{54-57}\)

Analysis

Biomarker results were merged with clinical and outcome information for analysis using SAS software and R. Descriptive statistics were used to compare biomarker status between patient groups. Patient-matched paired analyses were used to compare pretreatment and post-treatment samples, adjusting for baseline measurements; mRNA signatures were further adjusted for TcellinfGEP expression levels. The densities of CD8\(^{+}\), CD11c\(^{+}\), and FOXP3\(^{+}\) cells were analyzed on a logarithmic scale. Given the exploratory and hypothesis-generating nature of this study, no formal statistical testing was performed, but effect sizes for change from baseline and area under the receiver operator curve (AUROC) for group comparisons between groups and 95% CIs are presented.

RESULTS

Patients

A total of 124 patients met the original study criteria, with most tumors (n=110) considered to be anti-PD-1 therapy-resistant, while a smaller group of non-progressors (n=14) was also included (table 1). A total of 108 patients also met the criteria for classification of resistance according to the updated SITC-based definitions (table 1).\(^{53}\) Patient demographic, clinical, and treatment characteristics are summarized in table 2, with further details provided in online supplemental tables 1 and 2. The mean age at baseline biopsy was 59.5 (SD 12.4) years. Sixty-one percent of tumors were acral melanomas; 36% were mucosal melanomas; and 3% were unknown primaries but presumed to be mucosal melanomas; online supplemental table 3 provides patient characteristics by acral versus mucosal unknown histology. Most tumors were wild-type for the BRAF, KIT, and NRAS genes. Almost all (95%) of the patients included in the study had metastatic disease at the time of baseline biopsy. Eighty-seven percent of patients had no prior systemic therapy; all those who had received prior therapy (primarily dacarbazine) were in the resistant tumor group. Most patients (84%) received pembrolizumab as their anti-PD-1 therapy, with the remainder receiving nivolumab. At the time of data cut-off, the median duration of anti-PD-1 therapy was 6.3 (range 1.3–45.0) months among all patients, 23.2 (range 9.4–38.4) months among non-progressors, and 5.4 (range 1.3–45.0) months among patients with resistant tumors. The median duration of response among patients with resistant tumors was 4.7 months. Among the 14 non-progressors, half had a BOR of CR and half of PR; among patients with secondary resistance according to the original study definition, 61% had a BOR of CR, 44.9% of PR, and 49.0% of SD. All non-progressors were alive at the time of the last follow-up, compared with 46% of patients with resistant tumors (36% for primary-resistant tumors and 57% for secondary-resistant tumors).

When using the original definitions of primary and secondary resistance, the median duration of therapy was 2.8 months and 12.4 months, respectively, and the median duration of response was 1.6 months and 7.9 months. When using the SITC definition, the median duration of therapy for primary and secondary resistance was 3.5 months and 13.9 months, respectively, and the median duration of response was 1.9 months and 11.3 months.
Baseline biomarker differences between groups

The median baseline TMB for all patients was 130 mutations/exome, and 20% of tumors were classified as TMB-high (≥175 mutations/exome). The proportion of TMB-high tumors was numerically higher among the non-progressor group (40%) compared with the resistant group (17%) and for tumors with late secondary resistance (25%) compared with early secondary resistance (5%), but there was no difference in baseline TMB between primary-resistant and all secondary-resistant tumors (data not shown). The median baseline expression of the Tcell_int/GEP mRNA signature was numerically higher in

### Table 2  Patient demographic, clinical, and treatment characteristics *

| Characteristic                  | All patients (N=124) | Non-progressors (N=14) | Resistant (N=110) |
|---------------------------------|----------------------|------------------------|-------------------|
| Age                             | Mean (SD)            | 59.5 (12.4)            | 58.2 (12.7)       | 59.7 (12.4)       |
| Gender (binary)                 |                      |                        |                   |
| Female                          | 57 (46.0)            | 5 (35.7)               | 52 (47.3)         |
| Male                            | 67 (54.0)            | 9 (64.3)               | 58 (52.7)         |
| Histology                       |                      |                        |                   |
| Acral                           | 76 (61.3)            | 10 (71.4)              | 66 (60.0)         |
| Mucosal                         | 44 (35.5)            | 4 (28.6)               | 40 (36.4)         |
| Unknown primary†                | 4 (3.2)              | 0 (0.0)                | 4 (3.6)           |
| BRAF status                     |                      |                        |                   |
| Patients with data              | 122                  | 14                     | 108               |
| V600                            | 15 (12.3)            | 4 (28.6)               | 11 (10.2)         |
| WT                              | 105 (86.1)           | 10 (71.4)              | 95 (88.0)         |
| Other                           | 2 (1.6)              | 0 (0.0)                | 2 (1.9)           |
| M stage at baseline biopsy‡     |                      |                        |                   |
| M0                              | 6 (4.8)              | 3 (21.4)               | 3 (2.7)           |
| M1a                             | 44 (35.5)            | 2 (14.3)               | 42 (38.2)         |
| M1b                             | 9 (7.3)              | 1 (7.1)                | 8 (7.3)           |
| M1c                             | 65 (52.4)            | 8 (57.1)               | 57 (51.8)         |
| ECOG performance status         |                      |                        |                   |
| 1                               | 123 (99.2)           | 14 (100)               | 109 (99.1)        |
| 2                               | 1 (0.8)              | 0 (0.0)                | 1 (0.9)           |
| Rounds of previous systemic therapies |                  |                        |                   |
| 0                               | 108 (87.1)           | 14 (100)               | 94 (85.5)         |
| 1                               | 15 (12.1)            | 0 (0.0)                | 15 (13.6)         |
| 2                               | 1 (0.8)              | 0 (0.0)                | 1 (0.9)           |
| Type of anti-PD-1 treatment     |                      |                        |                   |
| Nivolumab                       | 20 (16.1)            | 4 (28.6)               | 16 (14.5)         |
| Pembrolizumab                   | 104 (83.9)           | 10 (71.4)              | 94 (85.5)         |
| Number of cycles received       |                      |                        |                   |
| Median (range)                  | 10 (2–67)            | 33 (14–67)             | 8 (2–64)          |
| Duration of anti-PD-1 treatment (months) |                  |                        |                   |
| Median (range)                  | 6.3 (1.3–45.0)       | 23.2 (9.4–38.4)‡       | 5.4 (1.3–45.0)    |

*All values given as N (%) unless otherwise stated.
†Only those unknown primary tumors with the clinical appearance of mucosal melanoma were included in the study.
‡M0, no distant metastases; M1a, non-visceral metastases to skin, soft tissue including muscles, and/or non-regional lymph nodes; M1b, distant metastases to the lung; M1c, all other visceral metastases and any distant metastases with elevated lactate dehydrogenase levels.
§Nine non-progressors were still on anti-PD-1 therapy at the time of data cut-off and were not included.
BRAF, B-raf proto-oncogene serine/threonine kinase; ECOG, Eastern Cooperative Oncology Group; PD-1, programmed cell death-1; WT, wild type.
non-progressor than in resistant tumors (AUROC) (0.78, 95% CI 0.62 to 0.94; online supplemental table 4 and figure 1). Following adjustment for Tcell_{iGEP}, none of the other mRNA expression signatures differed between these groups (online supplemental table 4). No baseline differences in any mRNA signature were observed between tumors displaying early versus late secondary resistance (data not shown).

Thirty-five percent of patients were classified as having PD-L1-positive tumors. The proportion of patients with PD-L1-positive tumors was numerically higher for non-progressors than for the resistant group (54% vs 32%), for the secondary than for the primary resistance group (original definition, 42% vs 24%; SITC definition, 43% vs 27%), and for late versus early secondary-resistant tumors under the original definition (60% vs 33%, online supplemental figure 1). The median baseline densities of infiltrating immune cells expressing CD8, CD11c, and FOXP3 were also numerically higher in non-progressors than in resistant tumors (online supplemental figure 1). The densities of CD8^{+} and FOXP3^{+} T cells were numerically higher in early versus late secondary-resistant tumors.

**Figure 1** Baseline characteristics of non-progressor and resistant tumors (A) Expression of an 18-gene Tcell_{iGEP}; (B) density of infiltrating immune cells expressing CD8; (C) density of infiltrating immune cells expressing CD11c; (D) density of infiltrating immune cells expressing FOXP3. Resistance was classified using the original study definitions. Box and whisker plots represent the distribution of biomarker values: median, first and third quartiles, minimum and maximum values. GEP, gene expression profile; Tcell_{iGEP}, T cell-inflamed gene expression profile.
tumors (AUROC=0.66 (95% CI 0.44 to 0.88) and 0.64 (0.44 to 0.85), respectively), but no difference was observed between these groups in the baseline density of CD11c+ T cells (AUROC=0.48 (95% CI 0.27 to 0.69)).

**Biomarker changes following treatment in resistant tumors**

Pretreatment and post-treatment samples were compared for all resistant tumors with available paired sample assay data. In resistant patients overall, immune cell infiltration markers and TMB did not change significantly between the baseline and post-treatment timepoints (data not shown). The proportion of PD-L1-positive tumors increased from a baseline level of 28% to 51% following treatment. The expression level of the TcellinfGEP mRNA signature increased in resistant tumors following treatment, while expression of the WNT and IFNA signatures decreased (online supplemental table 4 and figure 2).

**Biomarker differences between tumors with primary versus secondary resistance**

Following treatment, no differences in the magnitude of change from baseline for TMB or PD-L1 were observed between primary-resistant and secondary-resistant tumors, by either definition (data not shown). However, suggestive differences were observed for some mRNA signatures. Specifically, secondary-resistant tumors underwent a more pronounced change in expression of RAS-related and WNT-related signatures than did primary-resistant tumors; the difference was greater when patients were categorized using the SITC-based definitions (online supplemental table 4 and figure 3). In contrast, the change from baseline expression of an mRNA signature reflecting tumor infiltration with granulocytic myeloid-derived suppressor cells was greater in primary-resistant than in secondary-resistant tumors, with the difference being slightly smaller when the SITC-based definitions were used to distinguish the two groups (online supplemental table 4 and figure 3).

We also observed suggestive differences between primary-resistant and secondary-resistant tumors in terms of treatment-associated changes in markers of immune cell infiltration. The changes in the densities of CD11c+ and FOXP3+ T cells were greater in secondary-resistant than in primary-resistant tumors, with slightly greater differences in FOXP3 expression observed when distinguishing between groups using the SITC-based definitions of resistance (online supplemental table 5 and figure 3). Change from baseline CD11c+ cell density was numerically greater for early versus late secondary-resistant tumors (AUROC=0.69 (95% CI 0.45 to 0.93)), but this was not the case for CD8+ or FOXP3+ T cells (AUROC=0.61 (95% CI 0.39 to 0.85)) and 0.49 (95% CI 0.24 to 0.74), respectively, nor were any differences observed between these groups in the change from baseline of any mRNA signature tested (data not shown).

**DISCUSSION**

In this study, we observed suggestive molecular differences between baseline and post-treatment samples of anti-PD-1-resistant acral and mucosal melanomas, including changes related to TME T-cell inflammation and WNT and IFN signaling. We also found suggestive evidence of distinct differences between primary-resistant and secondary-resistant tumors in the magnitude of treatment-associated changes in RAS and WNT signaling, as well as T-cell infiltration. Further, we identified lower levels of TcellinfGEP, PD-L1, TMB, and immune cell infiltration (particularly by CD8+ T cells) as potential baseline predictors of resistance.

Our findings are consistent with previous reports that resistance to anti-PD-1 immunotherapy may involve suppression of T-cell function. Our observed increase in TcellinfGEP signature expression in resistant tumors during treatment is consistent with a recent report that anti-PD-1 therapy increased T-cell inflammatory...
Figure 3  Differences in post-treatment changes in primary versus secondary resistant tumors. (A–C) Expression of select RNA signatures, original study definitions of resistance. (A) gMDSCs, (B) WNT signaling, and (C) RAS signaling. (D,E) Expression of select RNA signatures; SITC definitions of resistance. (D) gMDSCs, (E) WNT signaling, and (F) RAS signaling. (G,H) Densities of infiltrating immune cells, original study definitions of resistance. (G) CD11c+ cells and (H) FOXP3+ cells. (I,J) densities of infiltrating immune cells; SITC definitions of resistance. (I) CD11c+ cells; (J) FOXP3+ cells. RNA expression values were adjusted for expression of an 18-gene TcellinfGEP. Box and whisker plots represent the distribution of biomarker values: median, first and third quartiles, and minimum and maximum values. Solid circles denote patients whose tumors were categorized as exhibiting secondary resistance using the original study definition but primary resistance using the SITC definition. gMDSC, granulocytic myeloid-derived suppressor cell; SITC, Society for Immunotherapy of Cancer; TcellinfGEP, T cell-inflamed gene expression profile.
observed a decrease in the IFNA signature. IFNA plays an important role in inducing tumor immunity; however, it may also have direct antiproliferative effects and thus may contribute to tumor resistance via non-immune-related mechanisms. 

In line with previous reports, we found that a lower baseline T-cell density was a strong predictor of resistance, particularly for CD8+ T cells. While we did not observe overall changes in immune cell density from baseline to post-treatment in resistant tumors, there was some evidence that tumors with secondary resistance underwent greater changes from baseline in FOXP3+ and CD11c+ cell density compared with primary-resistant tumors. The role of immune cell infiltrates in the TME is complex and there may be subset heterogeneity even within each type of immune cell marker. CD8+ T cells are key cytotoxic cells involved in antitumor activity, while CD11c+ T cells may represent a unique population of regulatory T cells with effector potential. CD11c expression may also be indicative of antigen-presenting dendritic cells that promote antitumor responses, but that can become defective and contribute to immune suppression. Cells with FOXP3 expression often have a T-regulatory function, but CD8+FOXP3+ T cells may also have lytic antitumor ability, depending on the TME.

Much of the prior work on anti-PD-1 therapy resistance was conducted in cutaneous superficial spreading melanomas. Understanding the distinct characteristics of acral and mucosal melanomas is crucial to the development of improved clinical guidelines for the treatment of these tumors. For example, we observed an association between lower baseline TMB and treatment resistance; we also observed that the median baseline TMB for our sample was lower than that previously reported for cutaneous superficial spreading melanomas, which are often driven by UV radiation-induced DNA damage. Given that TMB is related to tumor antigenicity and the ability of CD8+ T cells to localize to a tumor, this finding may indicate the need for distinct therapeutic approaches for melanomas with different etiologies, including additional methods to increase antigenicity.

Study limitations are noted. This was an exploratory study with a relatively small sample size, especially for analyses broken down by resistance subcategories, and we were unable to further stratify results by acral and mucosal subtypes due to sample size limitations. The results should be considered descriptive and hypothesis-generating and interpreted with caution. Nevertheless, this was to our knowledge the largest study to date to include comprehensive baseline and post-treatment characterization of acral and mucosal melanomas treated with anti-PD-1 monotherapy. The sample population was drawn from a single large tertiary teaching hospital, and more complex or severe cases of advanced melanoma may therefore be under-represented. For example, no patients with Eastern Cooperative Oncology Group grade 0 were included in the sample. Further, the population was selected based on resistant or long-term non-progressor status. Thus, the generalizability of the findings, especially to non-Asian populations, is unknown. Patient demographic and clinical characteristics were comprehensively described to facilitate comparisons to future study samples. No paired samples of non-progressor tumors were available, as post-treatment biopsies were not included in the standard of care for these individuals. Further, due to variation in the timing of post-treatment biopsies, comparisons of changes in biomarker profiles between tumors exhibiting primary and secondary resistance could be confounded by other potential factors that may change over time during the course of disease. Finally, although anti-PD-1 therapies are increasingly being used in combination with other agents, only tumors treated with anti-PD-1 monotherapy were included in the study; resistance mechanisms and biomarkers may be different in tumors treated with a combination of therapies.

In conclusion, this study reports initial evidence for several tumor baseline and treatment-associated characteristics, including markers of T-cell activity and RAS and WNT signaling, that may inform our understanding of resistance to anti-PD-1 monotherapy. The correlations reported herein should be considered for hypothesis-testing studies to determine their direct relevance to resistance mechanisms, which may lead to the development of combination therapies to restore immunotherapy efficacy. These results warrant additional investigation; conducting larger studies in these rarer melanoma types and further integrating these data with similar data from other studies would allow for confirmation of these findings as well as potential stratification between types. The acral and mucosal subtypes of melanoma are rare compared with cutaneous melanoma but present a significant clinical challenge in Asian populations due to their high relative prevalence and poor treatment outcomes with current approved therapies. Several mechanisms of resistance described in this study could be actionable with combination therapies, and future research directions should explore such combinations targeted toward these subtypes.

**Acknowledgements** The authors thank Li Ma, MS, Fansen Kong, MS, Jared Lunceford, PhD, and Steven Matthew Townsend, PhD of Merck & Co., Inc., Rahway, NJ, USA for their support. The authors also thank Cath Ennis, PhD, in collaboration with ScribCo for medical writing assistance.

**Contributors** IS: guarantor of the finished work; conception, design, or planning of the study; analysis of the data; acquisition of the data; drafting of the manuscript; and critically reviewing or revising the manuscript for important intellectual content. XQL: analysis of the data; interpretation of the results, and drafting of the manuscript. QZ: analysis of the data, drafting of the manuscript, and critically
reviewing or revising the manuscript for important intellectual content. STK: acquisition of the data, interpretation of the results, and drafting of the manuscript. YS: analysis of the data, acquisition of the data, and drafting of the manuscript. JHY and RC: analysis of the data, interpretation of the results, and critically reviewing or revising the manuscript for important intellectual content. AW and JL: conception, design, or planning of the study; and critically reviewing or revising the manuscript for important intellectual content. CK: conception, design, or planning of the study; analysis of the data; acquisition of the data; interpretation of the results; critically reviewing or revising the manuscript for important intellectual content.

Funding. The study was sponsored by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Rahway, New Jersey, USA.

Competing interests. IS, XLG, OZ, YS, JHY, TC, AW, CK, and RC are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Rahway, New Jersey, USA, and may have stock in Merck & Co., Rahway, New Jersey, USA. All remaining authors have declared no conflicts of interest.

Patient consent for publication. Not applicable.

Ethics approval. This study involves human subjects and was approved by the Samsung Medical Center institutional review board (IRB).

Provenance and peer review. Not commissioned; externally peer reviewed.

Data availability statement. Data are available upon reasonable request. Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Rahway, New Jersey, USA (MSD) is committed to providing qualified scientific researchers access to anonymized data and clinical study reports from the company’s clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial subjects and, as such, has a procedure in place for evaluating and fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data sharing website (available at http://engagezone.msd.com/de_documentation.php) outlines the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the USA and European Union or after product development is discontinued. There are circumstances that may prevent MSD from sharing requested data, including country-specific or region-specific regulations. If the request is declined, it will be communicated to the investigator.

Access to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and MSD subject matter experts; after approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to an analysis portal so that the requestor can perform the proposed analyses.

Supplemental material. This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been not commissioned; externally peer reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD. Irene M. Shui http://orcid.org/0000-0001-5737-9830

REFERENCES

1 Berwick M, Buller DB, Cust A, et al. Melanoma epidemiology and prevention. Cancer Treat Rev 2016;167:17–49.

2 Ferlay J, Shin H-R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917.

3 Glazer AM, Winkelnkemper RR, Farber AG, et al. Analysis of trends in US melanoma incidence and mortality. JAMA Dermatol 2015;153:225–6.

4 Kibbi N, Kluger H, Choi JN. Melanoma: clinical presentations. Cancer Treat Rev 2016;167:107–29.

5 Kim SY, Yun SJ. Cutaneous melanoma in Asians. Chonnam Med J 2016;52:185–93.

6 Namikawa K, Yamazaki N. Targeted therapy and immunotherapy for melanoma in Japan. Curr Treat Options Oncol 2019;20:7.

7 Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature 2017;545:175–80.

8 Pfeifer GP. Environmental exposures and mutational patterns of cancer genomes. Genome Med 2010;2:54.

9 Goydos JS, Shoen SL. Acral Lentiginous melanoma. Cancer Treat Rev 2016;167:321–9.

10 Mihajlovic M, Vlasic S, Jovanovic P, et al. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 2012;5:739–53.

11 Yeh I, Jorgenson E, Shen L, et al. Targeted genomic profiling of acral melanoma. J Natl Cancer Inst 2019;111:1068–77.

12 Bello DM, Chou JF, Bra gateas KS, et al. Analysis of acral melanoma: a series of 281 patients. Ann Surg Oncol 2013;20:3618–25.

13 Kuk D, Shoushtari AN, Barker CA, et al. Prognosis of mucosal, uveal, acral, Nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist 2016;21:848–54.

14 Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017;14:463–82.

15 Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134–44.

16 Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908–18.

17 Robert C, Long GV, Brady A, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320–30.

18 Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109–17.

19 Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521–32.

20 Topalian SL, Hodi F, Pardoll D, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.

21 Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020–30.

22 Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375–84.

23 Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016;315:1600–9.

24 Wang DY, Erogul Z, Ozgun A, et al. Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma. Cancer Immunol Res 2017;5:337–42.

25 Zaretzky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016;375:819–29.

26 Anagnostou V, Smith KN, Forde PM, et al. Evolution of neartigenic landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 2017;7:264–76.

27 Thomas NE, Busam KJ, Forde PM, et al. Tumor-Infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes environment and melanoma study. J Clin Oncol 2013;31:4262–9.

28 Tumeck PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–71.

29 Shin DS, Zaretzky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov 2017;7:188–201.
30 Gajewski TF, Louahed J, Briand VG, Gene signature in melanoma associated with clinical activity: a potential clue to uncover cancer immunotherapy. *Cancer J* 2010;16:399–403.

31 Gajewski TF, Schreiber H, Fu Y-K. Inductive and adaptive immune cells in the tumor microenvironment. *Nat Immunol* 2013;14:1014–22.

32 Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. *Cancer Res* 2009;69:3077–85.

33 Ji R-R, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. *Cancer Immunol Immunother* 2012;61:1019–31.

34 Grasso CS, Tosi J, Ornychchenko M, et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. *Cancer Cell* 2021;39:122.

35 D’Andello SP, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. *J Clin Oncol* 2017;35:226–35.

36 Hamid O, Robert C, Ribas A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001. *Cancer* 2018;119:670–40.

37 Maeda T, Yoshino K, Nagai K, et al. Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients. *Br J Dermatol* 2019;180:1230–1.

38 Namikawa K, Kiyohara Y, Takenouchi T, et al. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicentre phase II study. *Eur J Cancer* 2018;105:114–26.

39 Shoushtari AN, Munzho RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. *Cancer* 2016;122:3534–62.

40 Cristescu R, Auron-Garg D, Albright A. Association between tumor mutational burden (TMB) assessed by whole-exome sequencing (WES) and outcomes of pembrolizumab (pembro) monotherapy. paper presented at: annual meeting of the American association for cancer research 2020.

41 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–47.

42 Clugner HM, Tambi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance Taskforce. *J Immunother Cancer* 2020;8.

43 Daud AI, Wolchok JD, Robert C, et al. Programmed Death-Ligand 1 expression and response to the Anti-Programmed death 1 antibody pembrolizumab. *J Clin Oncol* 2016;34:4102–9.

44 BWA-MEM (computer program):114

45 McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010;20:1297–303.

46 Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol* 2013;31:213–9.

47 Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science* 2018;362, doi:10.1126/science.aar3593. [Epub ahead of print: 12 10 2018].

48 McLaren W, Gil L, Hunt SE, et al. The Ensembl variant effect predictor. *Genome Biol* 2016;17:122.

49 Riester M, Singh AP, Brannon AR, et al. PureCN: copy number calling tumor genomic biomarkers from targeted short read sequencing. *Source Code Biol Med* 2016;11:13.

50 Auron-Garg D, Albright A, Qiu P. Large-scale evaluation of concordance of genomic scores in whole exome sequencing and Foundation medicine comprehensive genomic platform across cancer types. *J Immunother Cancer* 2019;7.

51 Hu J, Ge H, Newman M, et al. OSA: a fast and accurate alignment tool for RNA-seq. *Bioinformatics* 2012;28:1933–4.

52 Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. *J Clin Invest* 2017;127:2930–40.

53 Cristescu R, Nebozhyn M, Zhang C. Pan-tumor analysis of the association of cancer and immune biology-related gene expression signatures with response to pembrolizumab monotherapy. *J Immunother Cancer* 2019;7.

54 Coppola D, Nebozhyn M, Khalil F, et al. Unique ectopic lymph node-like structures present in human primary colorectal cancers are identified by immune gene array profiling. *Am J Pathol* 2011;179:37–45.

55 Chaudhuri D, Quin C, Shen J, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. *Immunity* 2008;29:150–64.

56 Cristescu R, Nebozhyn M, Zhang C. Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types. *Clin Cancer Res* 2021.

57 Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell* 2015;27:45–61.

58 Chehrazi-Raffle F, Dorff TB, Pal SK, et al. Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. *Cancers* 2021;13. doi:10.3390/cancers13040889. [Epub ahead of print: 20 02 2021].

59 Coelho MA, de Carne Trécesson S, Rana S, et al. Oncogenic Ras signaling promotes tumor immunoresistance by stabilizing PD-1 mRNA. *Immunity* 2017;47:1083–99.

60 Goldsberry WN, Londoño A, Randall TD, et al. A review of the role of Wnt in cancer immunomodulation. *Cancers* 2019;11. doi:10.3390/cancers11070771. [Epub ahead of print: 04 06 2019].

61 Haas EL, Elewaut A, Gerard CL, et al. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. *Nat Cancer* 2021;2:693–706.

62 Lan N, White BS, Goussous G, et al. Kras mutation and consensus molecular subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer. *Clin Cancer Res* 2018;24:224–33.

63 Liao W, Overman MJ, Boutin AT, et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. *Cancer Cell* 2019;35:559–72.

64 Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, et al. Wnt signaling in tumors: the way to evade drugs and immunity. *Front Immunol* 2019;10:2854.

65 Zhong Z, Virshup DM. Wnt signaling and drug resistance in cancer. *Mol Pharmacol* 2020;97:72–88.

66 Grasso CS, Giannakis M, Wells DK, et al. Genetic mechanisms of immune evasion in colorectal cancer. *Cancer Discov* 2018;8:730–49.

67 Luke JJ, Bao R, Siews RF, et al. WNT/β-Catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. *Cancer Res* 2019;25:3074–83.

68 Naengimana J, Laye J, Filia A, et al. β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. *J Clin Invest* 2018;128:2048–63.

69 Spranger S, Ferrand L, Rafchi Y, et al. Impact of oncogenic pathways on evasion of antitumor immune responses. *Nat Rev Cancer* 2018;18:139–47.

70 Belardelli F, Ferrantini M, Proietti E, et al. Interferon-Alpha in tumor immunity and immunotherapy. *Cytokine Growth Factor Rev* 2002;13:119–34.

71 Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. *Nat Rev Cancer* 2016;16:131–44.

72 Chen H-Y, Xu L, Li F-R, et al. Inhibiting the CDB8+ T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radiosensitivity. *Sci Rep* 2018;8:11934.

73 Gide TN, Quek C, Menzies AM, et al. Distinct immune cell populations define response to anti-PD-1 immunotherapy and Anti-PD-1/Anti-CTLA-4 combined therapy. *Cancer Cell* 2019;35:238–55.

74 Farhood B, Najafi M, Mortezae K, et al. CDB8 cytotoxic T lymphocytes in cancer immunotherapy: A review. *J Cell Physiol* 2019;234:8509–21.

75 Vinay DS, Kwon BS, CD11c+CD8+ T cells: two-faced adaptive immune regulators. *Cell Immunol* 2010;264:18–22.

76 Veglia F, Gabriolovich D. Dendritic cells in cancer: the role revisited. *Curr Opin Immunol* 2017;45:43–51.

77 Le DT, Ladle BH, Lee T, et al. CDB8+ Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. *Int J Cancer* 2011;129:636–47.
SUPPLEMENTARY TABLES AND FIGURE
### Supplementary Table 1. Patient demographic and clinical characteristics

| Characteristic               | All patients (N = 124) | Non-progressors (N = 14) | Resistant (N = 110) | Original resistance definitions | SITC resistance definitions |
|-----------------------------|------------------------|--------------------------|---------------------|---------------------------------|----------------------------|
|                             |                        |                          |                     | Primary (N=61)                  | Secondary (N=49)            |
|                             |                        |                          |                     | Primary (N=76)                  | Secondary (N=32)            |
| Age                         | Mean (SD)              | 59.5 (12.4)              | 58.2 (12.7)         | 59.7 (12.4)                     | 60.1 (12.13)                |
|                             |                        |                          |                     |                                 | 59.3 (12.93)                |
|                             |                        |                          |                     |                                 | 60.1 (12.82)                |
|                             |                        |                          |                     |                                 | 59.5 (11.56)                |
| Gender (binary)             | Female                 | 57 (46.0)                | 5 (35.7)            | 52 (47.3)                       | 27 (44.3)                   |
|                             |                        |                          |                     |                                 | 25 (51.0)                   |
|                             | Male                   | 67 (54.0)                | 9 (64.3)            | 58 (52.7)                       | 34 (55.7)                   |
|                             |                        |                          |                     |                                 | 24 (49.0)                   |
|                             |                        |                          |                     |                                 | 37 (48.7)                   |
|                             |                        |                          |                     |                                 | 21 (65.6)                   |
| Histology                   | Acral                  | 76 (61.3)                | 10 (71.4)           | 66 (60.0)                       | 35 (57.4)                   |
|                             |                        |                          |                     |                                 | 31 (63.3)                   |
|                             | Mucosal                | 44 (35.5)                | 4 (28.6)            | 40 (36.4)                       | 24 (39.3)                   |
|                             |                        |                          |                     |                                 | 16 (32.7)                   |
|                             | Unknown primary a      | 4 (3.2)                  | 0 (0.0)             | 4 (3.6)                         | 2 (3.3)                     |
|                             |                        |                          |                     |                                 | 2 (4.1)                     |
|                             |                        |                          |                     |                                 | 3 (3.9)                     |
|                             |                        |                          |                     |                                 | 1 (3.1)                     |
| BRAF status                 | Patients with data     | 122                      | 14                  | 108                             | 60                         |
|                             | V600                   | 15 (12.3)                | 4 (28.6)            | 11 (10.2)                       | 6 (10.0)                   |
|                             |                         |                          |                     |                                 | 5 (10.4)                   |
|                             | WT                     | 105 (86.1)               | 10 (71.4)           | 95 (88.0)                       | 54 (90.0)                  |
|                             |                         |                          |                     |                                 | 41 (85.4)                  |
|                             | Other                  | 2 (1.6)                  | 0 (0.0)             | 2 (1.9)                         | 0 (0.0)                    |
|                             |                         |                          |                     |                                 | 2 (4.2)                    |
|                             |                         |                          |                     |                                 | 1 (1.3)                    |
|                             |                         |                          |                     |                                 | 1 (3.2)                    |
| KIT status                  | Patients with data     | 104                      | 12                  | 92                              | 49                         |
|                             | Mutant                 | 5 (4.8)                  | 0 (0.0)             | 5 (5.4)                         | 0 (0.0)                    |
|                             |                         |                          |                     |                                 | 5 (11.6)                   |
|                             |                         |                          |                     |                                 | 3 (4.8)                    |
|                             |                         |                          |                     |                                 | 2 (7.1)                    |
| Characteristic | All patients \((N = 124)\) | Non-progressors \((N = 14)\) | Resistant \((N = 110)\) | Original resistance definitions | SITC resistance definitions |
|---------------|-----------------------------|-------------------------------|--------------------------|--------------------------------|-----------------------------|
|               |                             |                               |                          | Primary \((N = 61)\) | Secondary \((N = 49)\) | Primary \((N = 76)\) | Secondary \((N = 32)\) |
| WT            | 99 (95.2)                  | 12 (100)                     | 87 (94.6)                | 49 (100.0)          | 38 (88.4)             | 59 (95.2)          | 26 (92.9)          |
| NRAS status   |                             |                               |                          |                  |                           |                  |                           |
| Patients with data | 104                        | 11                            | 93                       | 49                | 44                       | 61                | 30                       |
| Mutant        | 15 (14.4)                  | 1 (9.1)                      | 14 (15.1)                | 9 (18.4)          | 5 (11.4)                | 10 (16.4)        | 4 (13.3)               |
| WT            | 89 (85.6)                  | 10 (90.9)                    | 79 (84.9)                | 40 (81.6)         | 39 (88.6)               | 51 (83.6)        | 26 (86.7)              |
| M stage at baseline biopsy |             |                               |                          |                  |                           |                  |                           |
| M0            | 6 (4.8)                    | 3 (21.4)                     | 3 (2.7)                  | 2 (3.3)           | 1 (2.0)                  | 2 (2.6)          | 1 (3.1)                 |
| M1a           | 44 (35.5)                  | 2 (14.3)                     | 42 (38.2)                | 27 (44.3)         | 15 (30.6)               | 34 (44.7)        | 7 (21.9)                |
| M1b           | 9 (7.3)                    | 1 (7.1)                      | 8 (7.3)                  | 3 (4.9)           | 5 (10.2)                | 3 (3.9)          | 4 (12.5)                |
| M1c           | 65 (52.4)                  | 8 (57.1)                     | 57 (51.8)                | 29 (47.5)         | 28 (57.1)               | 37 (48.7)        | 20 (62.5)               |
| Metastasis at baseline biopsy |           |                               |                          |                  |                           |                  |                           |
| Brain         | 6 (4.8)                    | 1 (7.1)                      | 5 (4.5)                  | 4 (6.6)           | 1 (2.0)                  | 5 (6.6)          | 0 (0.0)                 |
| Liver         | 18 (14.5)                  | 1 (7.1)                      | 17 (15.5)                | 11 (18.0)         | 6 (12.2)                 | 14 (18.4)        | 3 (9.4)                 |
| ECOG performance status |         |                               |                          |                  |                           |                  |                           |
| 1             | 123 (99.2)                 | 14 (100)                     | 109 (99.1)               | 60 (98.4)         | 49 (100.0)              | 75 (98.7)        | 32 (100.0)              |
| 2             | 1 (0.8)                    | 0 (0.0)                      | 1 (0.9)                  | 1 (1.6)           | 0 (0.0)                  | 1 (1.3)          | 0 (0.0)                 |
| Serum lactase dehydrogenase status at initiation of anti-PD-1 | | | | | | | |
| Characteristic                        | All patients (N = 124) | Non-progressors (N = 14) | Resistant (N = 110) | Original resistance definitions | SITC resistance definitions |
|--------------------------------------|------------------------|--------------------------|---------------------|---------------------------------|-----------------------------|
|                                     |                        |                          |                     | Primary (N=61)                  | Secondary (N=49)            |                          |
|                                     |                        |                          |                     | Primary (N=76)                  | Secondary (N=32)            |                          |
| therapy                             |                        |                          |                     |                                 |                             |                          |
| Elevated                            | 16 (12.9)              | 1 (7.1)                  | 15 (13.6)           | 11 (18.0)                       | 4 (8.2)                     | 12 (15.8)                 | 3 (9.4)                 |
| Normal                              | 93 (75.0)              | 12 (85.7)                | 81 (73.6)           | 42 (68.9)                       | 39 (79.6)                   | 54 (71.1)                 | 26 (81.3)               |
| Unknown                             | 15 (12.1)              | 1 (7.1)                  | 14 (12.7)           | 8 (13.1)                        | 6 (12.2)                    | 10 (13.2)                 | 3 (9.4)                 |
| Neutrophil to lymphocyte ratio      |                        |                          |                     |                                 |                             |                          |
| Mean (SD)                           | 2.1 (0.1)              | 1.8 (0.5)                | 2.1 (1.0)           | 2.3 (1.0)                       | 2.0 (1.0)                   | 2.14 (0.981)              | 2.13 (1.199)            |
| Median (range)                      | 1.9 (0.7–6.2)          | 1.6 (1.2–3.0)            | 1.9 (0.7–6.2)       | 2.0 (0.9–5.4)                   | 1.8 (0.7–6.2)               | 1.87 (0.7–5.4)            | 1.90 (0.9–6.2)          |
| Rounds of previous systemic therapies|                        |                          |                     |                                 |                             |                          |
| 0                                   | 108 (87.1)             | 14 (100)                 | 94 (85.5)           | 51 (83.6)                       | 43 (87.8)                   | 63 (82.9)                 | 29 (90.6)               |
| 1                                   | 15 (12.1)              | 0 (0.0)                  | 15 (13.6)           | 9 (14.8)                        | 6 (12.2)                    | 12 (15.8)                 | 3 (9.4)                 |
| 2                                   | 1 (0.8)                | 0 (0.0)                  | 1 (0.9)             | 1 (1.6)                         | 0 (0.0)                     | 1 (1.3)                   | 0 (0.0)                 |
| Type of previous systemic therapy   |                        |                          |                     |                                 |                             |                          |
| Patients with data                  | 16                     | 0                        | 16                  | 10                              | 6                           | 13                        | 3                       |
| BRAF and/or MEK/MAP2K inhibitor     | 2 (12.5)               | NA                       | 2 (12.5)            | 2 (20.0)                        | 0 (0.0)                     | 2 (15.4)                  | 0 (0.0)                 |
| CTLA-4 inhibitor                    | 1 (6.3)                | NA                       | 1 (6.3)             | 1 (10.0)                        | 0 (0.0)                     | 1 (7.7)                   | 0 (0.0)                 |
| Dacarbazine or CVD                  | 12 (75.0)              | NA                       | 12 (75.0)           | 7 (70.0)                        | 5 (83.3)                    | 9 (69.2)                  | 3 (100.0)               |
| Characteristic                  | All patients (N = 124) | Non-progressors (N = 14) | Resistant (N = 110) | Original resistance definitions | SITC resistance definitions |
|--------------------------------|------------------------|--------------------------|---------------------|---------------------------------|------------------------------|
|                                |                        |                          |                     | Primary (N=61)                  | Secondary (N=49)             |
|                                |                        |                          |                     | Primary (N=76)                  | Secondary (N=32)             |
| Paclitaxel + carboplatin       | 1 (6.3)                | NA                       | 1 (6.3)             | 0 (0.0)                         | 1 (16.7)                     |
|                                |                        |                          |                     |                                 | 1 (7.7)                      |
|                                |                        |                          |                     |                                 | 0 (0.0)                      |
| Site of baseline biopsy        |                        |                          |                     |                                 |                              |
| Patients with data             | 124                    | 14                       | 110                 | 61                              | 49                           |
|                                |                        |                          |                     |                                 | 76                           |
|                                |                        |                          |                     |                                 | 32                           |
| Skin                           | 56 (45.2)              | 2 (14.3)                 | 54 (49.1)           | 28 (45.9)                       | 26 (53.1)                    |
|                                |                        |                          |                     |                                 | 36 (47.4)                    |
|                                |                        |                          |                     |                                 | 16 (50.0)                    |
| Lymph node                     | 24 (19.4)              | 5 (35.7)                 | 19 (17.3)           | 10 (16.4)                       | 9 (18.4)                     |
|                                |                        |                          |                     |                                 | 14 (18.4)                    |
|                                |                        |                          |                     |                                 | 5 (15.6)                     |
| Mucosal surface                | 21 (16.9)              | 3 (21.4)                 | 18 (16.4)           | 12 (19.7)                       | 6 (12.2)                     |
|                                |                        |                          |                     |                                 | 13 (17.1)                    |
|                                |                        |                          |                     |                                 | 5 (15.6)                     |
| Other                          | 23 (18.6)              | 4 (28.6)                 | 19 (17.3)           | 11 (18.0)                       | 8 (16.3)                     |
|                                |                        |                          |                     |                                 | 13 (17.1)                    |
|                                |                        |                          |                     |                                 | 6 (18.8)                     |
| Site of Post-treatment biopsy  |                        |                          |                     |                                 |                              |
| Patients with data             | NA                     | NA                       | 90                  | 53                              | 37                           |
|                                |                        |                          |                     |                                 | 68                           |
|                                |                        |                          |                     |                                 | 21                           |
| Skin                           | NA                     | NA                       | 30 (33.3)           | 15 (28.3)                       | 15 (40.5)                    |
|                                |                        |                          |                     |                                 | 20 (29.4)                    |
|                                |                        |                          |                     |                                 | 9 (42.9)                     |
| Lymph node                     | NA                     | NA                       | 19 (21.1)           | 12 (22.6)                       | 7 (18.9)                     |
|                                |                        |                          |                     |                                 | 16 (23.5)                    |
|                                |                        |                          |                     |                                 | 3 (14.3)                     |
| Mucosal surface                | NA                     | NA                       | 10 (11.1)           | 5 (9.4)                         | 5 (13.5)                     |
|                                |                        |                          |                     |                                 | 7 (10.3)                     |
|                                |                        |                          |                     |                                 | 3 (14.3)                     |
| Other                          | NA                     | NA                       | 31 (34.4)           | 21 (39.6)                       | 10 (27.0)                    |
|                                |                        |                          |                     |                                 | 25 (36.8)                    |
|                                |                        |                          |                     |                                 | 6 (28.6)                     |

CVD, cisplatin, vinblastine and dacarbazine; ECOG, Eastern Cooperative Oncology Group; NA, not applicable; SD, standard deviation; SITC, Society for Immunotherapy of Cancer; WT, wild-type.

A All values given as n (%) unless otherwise stated.

B Only those unknown primary tumors with the clinical appearance of mucosal melanoma were included in the study.

C M0, no distant metastases; M1a, non-visceral metastases to skin, soft tissue including muscles, and/or nonregional lymph nodes; M1b, distant metastases to lung; M1c, all other visceral metastases and any distant metastases with elevated lactase dehydrogenase levels.
### Supplementary Table 2. Patient treatment and clinical outcomes

|                          | All patients \(N = 124\) | Non-progressors \(N = 14\) | Resistant \(N = 110\) | Original resistance definitions | SITC resistance definitions |
|--------------------------|---------------------------|----------------------------|-----------------------|---------------------------------|-----------------------------|
|                          |                           |                            |                       | Primary                         | Secondary                   |
| Type of anti-PD-1 treatment |                           |                            |                       |                                 |                             |
| Nivolumab                | 20 (16.1)                 | 4 (28.6)                   | 16 (14.5)             | 6 (9.8)                         | 10 (20.4)                   |
| Pembrolizumab            | 104 (83.9)                | 10 (71.4)                  | 94 (85.5)             | 55 (90.2)                       | 39 (79.6)                   |
| Number of cycles received |                           |                            |                       |                                 |                             |
| Median (range)           | 10 (2–67)                 | 33 (14–67)                 | 8 (2–64)              | 5.0 (2–27)                      | 19.0 (5–64)                 |
| Duration of anti-PD-1 treatment (months) |                           |                            |                       |                                 |                             |
| Median (range)           | 6.3 (1.3–45.0)            | 23.2 (9.4–38.4)            | 5.4 (1.3–45.0)        | 2.79 (1.3–18.4)                 | 12.45 (3.7–45.0)            |
| Duration of response (months) C |                           |                            |                       |                                 |                             |
| Patients with data       | 94                        | 14                         | 80                    | 31                              | 46                          |
| Median (range)           | 6.0 (0.0–44.5)            | 27.2 (15.6–44.5)           | 4.7 (0.0–40.7)        | 1.64 (0.0–2.9)                  | 7.87 (3.1–40.7)            |
| Best overall response    |                           |                            |                       |                                 |                             |
| Complete response        | 11 (8.9)                  | 7 (50.0)                   | 4 (3.6)               | 1 (1.6)                         | 3 (6.1)                     |
| Partial response         | 35 (28.2)                 | 7 (50.0)                   | 28 (25.5)             | 6 (9.8)                         | 22 (44.9)                   |
| Stable disease           | 48 (38.7)                 | 0 (0.0)                    | 48 (43.6)             | 24 (39.3)                       | 24 (49.0)                   |
|                                | All patients (N = 124) | Non-progressors (N = 14) | Resistant (N = 110) | Original resistance definitions | SITC resistance definitions |
|--------------------------------|------------------------|--------------------------|---------------------|---------------------------------|-----------------------------|
|                                |                        |                          |                     | Primary                        | Primary                     |
|                                |                        |                          |                     | Secondary                       | Secondary                   |
| Progressive disease            | 30 (24.2)              | 0 (0.0)                  | 30 (27.3)           | 30 (49.2)                       | 30 (39.5)                   |
| Vital status at last follow-up |                        |                          |                     | 0 (0.0)                         | 0 (0.0)                     |
| Alive                          | 64 (51.6)              | 14 (100)                 | 50 (45.5)           | 22 (36.1)                       | 27 (35.5)                   |
|                                |                        |                          |                     | 28 (57.1)                       | 21 (65.6)                   |
| Dead                           | 60 (48.4)              | 0 (0.0)                  | 60 (54.5)           | 39 (63.9)                       | 49 (64.5)                   |
|                                |                        |                          |                     | 21 (42.9)                       | 11 (34.4)                   |

SD, standard deviation; SITC, Society for Immunotherapy of Cancer.

A All values given as n (%) unless otherwise stated.
B Date of last follow-up was used to calculate duration of therapy and response for 9 non-responders whose treatment was ongoing at the end of the study period.
C Duration of response is reported for patients with a best overall response of complete response, partial response, and stable disease. Patients with BOR of CR, PR, or SD <90 days (original definition) and <180 days (SITC definition) before progression are considered primary resistance. Patients with a BOR of ≥90 days (original definition) and ≥180 days (SITC definition) before progression are considered secondary resistance.
### Supplementary Table 3. Patient characteristics by acral and mucosal melanoma

| Characteristic                        | Acral (N = 76) | Mucosal/Unknown Primary (N = 48) |
|---------------------------------------|----------------|----------------------------------|
| Age                                   |                |                                  |
| Mean (SD)                             | 58.9 (12.38)   | 60.5 (12.6)                      |
| Gender                                |                |                                  |
| Female                                | 34 (44.7)      | 23 (47.9)                        |
| Male                                  | 42 (55.3)      | 25 (52.1)                        |
| BRAF status                           |                |                                  |
| Subjects with data                    | 74             | 48                               |
| V600                                  | 11 (14.9)      | 4 (8.3)                          |
| WT                                    | 62 (83.8)      | 43 (89.6)                        |
| Other                                 | 1 (1.4)        | 1 (2.1)                          |
| M stage at biopsy                     |                |                                  |
| M0                                    | 1 (1.3)        | 5 (10.4)                         |
| M1a                                   | 32 (42.1)      | 12 (25.0)                        |
| M1b                                   | 5 (6.6)        | 4 (8.3)                          |
| M1c                                   | 38 (50.0)      | 27 (56.3)                        |
| ECOG performance status               |                |                                  |
| 1                                     | 76 (100.0)     | 44 (97.9)                        |
| 2                                     | 0 (0.0)        | 1 (2.1)                          |
| Lines of previous systemic therapy    |                |                                  |
| 0                                     | 64 (84.2)      | 4 (90.9)                         |
| 1                                     | 11 (14.5)      | 4 (9.1)                          |
| 2                                     | 1 (1.3)        | 0 (0.0)                          |
| Type of previous systemic therapy     |                |                                  |
| Subjects with data                    | 12             | 4                                |
| BRAF and/or MEK inhibitor             | 1 (8.3)        | 1 (25.0)                         |
| CTLA-4 inhibitor                      | 0 (0.0)        | 1 (25.0)                         |
| Dacarbazine                           | 10 (83.3)      | 2 (50.0)                         |
| Paclitaxel + carboplatin              | 1 (8.3)        | 0 (0.0)                          |
| Type of anti-PD-1 treatment           |                |                                  |
| Nivolumab                             | 12 (15.8)      | 8 (16.7)                         |
|                          | Pembrolizumab |       |
|--------------------------|---------------|-------|
| Cycles received          |               |       |
| Median (range)           | 64 (84.2)     | 40 (83.3) |
| Duration of anti-PD-1 treatment (months) |               |       |
| Median (range)           | 10 (2.67)     | 11.5 (2, 50) |

ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; WT, wild-type.

^ All values given as n (%) unless otherwise stated.

M0, no distant metastases; M1a, non-visceral metastases to skin, soft tissue including muscles, and/or nonregional lymph nodes; M1b, distant metastases to lung; M1c, all other visceral metastases and any distant metastases with elevated lactase dehydrogenase levels.
**Supplementary Table 4. Baseline and post-treatment comparisons of mRNA signature expression levels in the non-progressor and resistant groups**

| mRNA signature (number of genes in consensus gene set) | Baseline expression, non-progressors versus resistant AUROC (95% CI) | Post-treatment change from baseline, resistant Effect size (95% CI) | Post-treatment change from baseline, primary versus secondary resistance AUROC (95% CI) | Original study definition | SITC definition |
|--------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|----------------------------|-----------------|
| GEP (18)                                               | 0.78 (0.62, 0.94)                                              | 0.34 (−0.15, 0.80)                                            | 0.53 (0.37, 0.68)                                              | (0.33, 0.68)               |
| Angiogenesis (16)                                      | 0.62 (0.46, 0.78)                                              | 0.07 (−0.31, 0.45)                                            | 0.48 (0.32, 0.64)                                              | (0.41, 0.77)               |
| Glycolysis (30)                                        | 0.59 (0.37, 0.81)                                              | −0.12 (−0.50, 0.26)                                           | 0.51 (0.35, 0.67)                                              | (0.35, 0.72)               |
| Hypoxia (20)                                           | 0.61 (0.39, 0.83)                                              | −0.07 (−0.45, 0.31)                                           | 0.51 (0.35, 0.67)                                              | (0.29, 0.65)               |
| gMDSC (43)                                             | 0.51 (0.31, 0.70)                                              | −0.03 (−0.41, 0.35)                                           | 0.63 (0.48, 0.79)                                              | (0.42, 0.78)               |
| mMDSC (218)                                            | 0.61 (0.44, 0.77)                                              | 0.23 (−0.15, 0.61)                                            | 0.60 (0.45, 0.75)                                              | (0.46, 0.76)               |
| MYC (32)                                               | 0.56 (0.35, 0.77)                                              | 0.23 (−0.15, 0.61)                                            | 0.61 (0.46, 0.77)                                              | (0.42, 0.77)               |
| Proliferation (227)                                    | 0.55 (0.34, 0.77)                                              | 0.03 (−0.35, 0.41)                                            | 0.61 (0.46, 0.76)                                              | (0.36, 0.75)               |
| RAS (11)                                               | 0.49 (0.27, 0.71)                                              | −0.09 (−0.46, 0.29)                                           | 0.57 (0.42, 0.73)                                              | (0.51, 0.84)               |
| Stroma/EMT/TGFB1 (51)                                  | 0.63 (0.45, 0.81)                                              | −0.12 (−0.50, 0.26)                                           | 0.50 (0.34, 0.66)                                              | (0.27, 0.63)               |
| WNT (13)                                               | 0.47 (0.30, 0.64)                                              | −0.42 (−0.81, −0.04)                                          | 0.57 (0.42, 0.73)                                              | (0.62, 0.90)               |
| IFNA1 (3)                                              | 0.48 (0.32, 0.65)                                              | −0.50 (−0.89, −0.11)                                          | 0.57 (0.42, 0.73)                                              | (0.36, 0.71)               |
| Cytokine (12)                                          | 0.58 (0.38, 0.77)                                              | −0.01 (−0.38, 0.37)                                           | 0.57 (0.41, 0.73)                                              | (0.47, 0.77)               |

AUROC, area under the receiver operating characteristic; CI, confidence interval; EMT, epithelial-to-mesenchymal transition; GEP, 18-gene T cell-inflamed gene expression profile (Tcell-infGEP); gMDSC, granulocytic myeloid-derived suppressor cells; mMDSC, monocytic myeloid-derived suppressor cells; SITC, Society for Immunotherapy of Cancer.

*All mRNA signatures other than GEP were adjusted for GEP values.*
**Supplementary Table 5. Baseline and post-treatment comparisons of infiltrating immune cell densities in the non-progressor and resistant groups**

| Cell type | Baseline expression, non-progressors versus resistant | Post-treatment change from baseline, primary versus secondary resistance | Original study definition | SITC definition |
|-----------|-----------------------------------------------------|---------------------------------------------------------------------|--------------------------|-----------------|
| CD8⁺      | 0.78 (0.65, 0.90)                                    | 0.53 (0.39, 0.67)                                                   | 0.58 (0.43, 0.73)       |
| CD11c⁺    | 0.70 (0.54, 0.87)                                    | 0.60 (0.46, 0.75)                                                   | 0.62 (0.45, 0.78)       |
| FOXP3⁺    | 0.73 (0.54, 0.87)                                    | 0.58 (0.44, 0.71)                                                   | 0.69 (0.55, 0.83)       |

SITC, Society for Immunotherapy of Cancer.

All values given as area under the receiver operating characteristic (95% confidence interval)
Supplementary Figure 1. Percent PD-L1 MEL score ≥2 at baseline

- Resistant (n=100): 32%
- Non-Progressor (n=13): 54%
- Primary resistant (n=55): 24%
- Secondary resistant (n=45): 42%
- Early secondary (n=30): 33%
- Late secondary (n=15): 60%

*Based on primary definitions of resistance.
SUPPLEMENTARY TABLES AND FIGURE
Supplementary Table 1. Patient demographic and clinical characteristics\textsuperscript{A}

| Characteristic | All patients (N = 124) | Non-progressors (N = 14) | Resistant (N = 110) | Original resistance definitions | SITC resistance definitions |
|----------------|------------------------|--------------------------|---------------------|-------------------------------|-----------------------------|
|                |                        |                          |                     | Primary (N=61) | Secondary (N=49) | Primary (N=76) | Secondary (N=32) |
| Age            | Mean (SD)              | 59.5 (12.4)              | 58.2 (12.7)         | 59.7 (12.4) | 60.1 (12.13) | 59.3 (12.93) | 60.1 (12.82) | 59.5 (11.56) |
| Gender (binary)| Female                 | 57 (46.0)                | 5 (35.7)            | 52 (47.3)  | 27 (44.3)   | 25 (51.0)   | 39 (51.3)   | 11 (34.4)   |
|                | Male                   | 67 (54.0)                | 9 (64.3)            | 58 (52.7)  | 34 (55.7)   | 24 (49.0)   | 37 (48.7)   | 21 (65.6)   |
| Histology      | Acral                  | 76 (61.3)                | 10 (71.4)           | 66 (60.0)  | 35 (57.4)   | 31 (63.3)   | 46 (60.5)   | 19 (59.4)   |
|                | Mucosal                | 44 (35.5)                | 4 (28.6)            | 40 (36.4)  | 24 (39.3)   | 16 (32.7)   | 27 (35.5)   | 12 (37.5)   |
|                | Unknown primary\textsuperscript{B} | 4 (3.2)                 | 0 (0.0)             | 4 (3.6)    | 2 (3.3)     | 2 (4.1)     | 3 (3.9)     | 1 (3.1)     |
| **BRAF** status| Patients with data     | 122                      | 14                  | 108         | 60          | 48          | 75          | 31          |
|                | V600                   | 15 (12.3)                | 4 (28.6)            | 11 (10.2)  | 6 (10.0)    | 5 (10.4)    | 7 (9.3)     | 4 (12.9)    |
|                | WT                     | 105 (86.1)               | 10 (71.4)           | 95 (88.0)  | 54 (90.0)   | 41 (85.4)   | 67 (89.3)   | 26 (83.9)   |
|                | Other                  | 2 (1.6)                  | 0 (0.0)             | 2 (1.9)    | 0 (0.0)     | 2 (4.2)     | 1 (1.3)     | 1 (3.2)     |
| **KIT** status | Patients with data     | 104                      | 12                  | 92          | 49          | 43          | 62          | 28          |
|                | Mutant                 | 5 (4.8)                  | 0 (0.0)             | 5 (5.4)    | 0 (0.0)     | 5 (11.6)    | 3 (4.8)     | 2 (7.1)     |
| Characteristic                          | All patients (N = 124) | Non-progressors (N = 14) | Resistant (N = 110) | Original resistance definitions | SITC resistance definitions |
|----------------------------------------|------------------------|--------------------------|---------------------|--------------------------------|-----------------------------|
|                                        |                        |                          |                     | Primary (N=61)                | Secondary (N=49)            |
|                                        |                        |                          |                     | Primary (N=76)                | Secondary (N=32)            |
| WT                                     | 99 (95.2)              | 12 (100)                 | 87 (94.6)           | 49 (100.0)                    | 38 (88.4)                   |
|                                        |                        |                          |                     | 59 (95.2)                     | 26 (92.9)                   |
| NRAS status                            |                        |                          |                     |                                |                            |
| Patients with data                     | 104                    | 11                       | 93                  | 49                             | 44                          |
|                                        |                        |                          |                     | 61                             | 30                          |
| Mutant                                 | 15 (14.4)              | 1 (9.1)                  | 14 (15.1)           | 9 (18.4)                      | 5 (11.4)                    |
|                                        |                        |                          |                     | 10 (16.4)                     | 4 (13.3)                    |
| WT                                     | 89 (85.6)              | 10 (90.9)                | 79 (84.9)           | 40 (81.6)                     | 39 (88.6)                   |
|                                        |                        |                          |                     | 51 (83.6)                     | 26 (86.7)                   |
| M stage at baseline biopsy             |                        |                          |                     |                                |                            |
| c                                      |                        |                          |                     |                                |                            |
| M0                                     | 6 (4.8)                | 3 (21.4)                 | 3 (2.7)             | 2 (3.3)                       | 1 (2.0)                     |
|                                        |                        |                          |                     | 2 (2.6)                       | 1 (3.1)                     |
| M1a                                    | 44 (35.5)              | 2 (14.3)                 | 42 (38.2)           | 27 (44.3)                     | 15 (30.6)                   |
|                                        |                        |                          |                     | 34 (44.7)                     | 7 (21.9)                    |
| M1b                                    | 9 (7.3)                | 1 (7.1)                  | 8 (7.3)             | 3 (4.9)                       | 5 (10.2)                    |
|                                        |                        |                          |                     | 3 (3.9)                       | 4 (12.5)                    |
| M1c                                    | 65 (52.4)              | 8 (57.1)                 | 57 (51.8)           | 29 (47.5)                     | 28 (57.1)                   |
|                                        |                        |                          |                     | 37 (48.7)                     | 20 (62.5)                   |
| Metastasis at baseline biopsy          |                        |                          |                     |                                |                            |
|                                        |                        |                          |                     |                                |                            |
| Brain                                  | 6 (4.8)                | 1 (7.1)                  | 5 (4.5)             | 4 (6.6)                       | 1 (2.0)                     |
|                                        |                        |                          |                     | 5 (6.6)                       | 0 (0.0)                     |
| Liver                                  | 18 (14.5)              | 1 (7.1)                  | 17 (15.5)           | 11 (18.0)                     | 6 (12.2)                    |
|                                        |                        |                          |                     | 14 (18.4)                     | 3 (9.4)                     |
| ECOG performance status                |                        |                          |                     |                                |                            |
|                                        |                        |                          |                     |                                |                            |
| 1                                      | 123 (99.2)             | 14 (100)                 | 109 (99.1)          | 60 (98.4)                     | 49 (100.0)                  |
|                                        |                        |                          |                     | 75 (98.7)                     | 32 (100.0)                  |
| 2                                      | 1 (0.8)                | 0 (0.0)                  | 1 (0.9)             | 1 (1.6)                       | 0 (0.0)                     |
|                                        |                        |                          |                     | 1 (1.3)                       | 0 (0.0)                     |
| Serum lactase dehydrogenase status at  |                        |                          |                     |                                |                            |
| initiation of anti-PD-1                |                        |                          |                     |                                |                            |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
| Characteristic                        | All patients (N = 124) | Non-progressors (N = 14) | Resistant (N = 110) | Original resistance definitions | SITC resistance definitions |
|--------------------------------------|------------------------|--------------------------|---------------------|--------------------------------|---------------------------|
|                                      | Primary (N=61)         | Secondary (N=49)         | Primary (N=76)      | Secondary (N=32)                |
| therapy                              |                        |                          |                     |                                |
| Elevated                             | 16 (12.9)              | 1 (7.1)                  | 15 (13.6)            | 11 (18.0)                      | 4 (8.2)                   | 12 (15.8)                                      | 3 (9.4)                                      |
| Normal                               | 93 (75.0)              | 12 (85.7)                | 81 (73.6)            | 42 (68.9)                      | 39 (79.6)                 | 54 (71.1)                                      | 26 (81.3)                                     |
| Unknown                              | 15 (12.1)              | 1 (7.1)                  | 14 (12.7)            | 8 (13.1)                       | 6 (12.2)                  | 10 (13.2)                                      | 3 (9.4)                                      |
| Neutrophil to lymphocyte ratio       |                        |                          |                     |                                |                          |                                                |                                            |
| Mean (SD)                            | 2.1 (0.1)              | 1.8 (0.5)                | 2.1 (1.0)            | 2.3 (1.0)                      | 2.0 (1.0)                 | 2.14 (0.981)                                   | 2.13 (1.119)                                  |
| Median (range)                       | 1.9 (0.7–6.2)          | 1.6 (1.2–3.0)            | 1.9 (0.7–6.2)        | 2.0 (0.9–5.4)                  | 1.8 (0.7–6.2)             | 1.87 (0.7–5.4)                                 | 1.90 (0.9–6.2)                               |
| Rounds of previous systemic therapies|                        |                          |                     |                                |                          |                                                |                                            |
| 0                                    | 108 (87.1)             | 14 (100)                 | 94 (85.5)            | 51 (83.6)                      | 43 (87.8)                 | 63 (82.9)                                      | 29 (90.6)                                    |
| 1                                    | 15 (12.1)              | 0 (0.0)                  | 15 (13.6)            | 9 (14.8)                       | 6 (12.2)                  | 12 (15.8)                                      | 3 (9.4)                                      |
| 2                                    | 1 (0.8)                | 0 (0.0)                  | 1 (0.9)              | 1 (1.6)                        | 0 (0.0)                   | 1 (1.3)                                        | 0 (0.0)                                      |
| Type of previous systemic therapy    |                        |                          |                     |                                |                          |                                                |                                            |
| Patients with data                   | 16                     | 0                        | 16                   | 10                             | 6                         | 13                                             | 3                                            |
| BRAF and/or MEK/MAP2K inhibitor      | 2 (12.5)               | NA                       | 2 (12.5)             | 2 (20.0)                       | 0 (0.0)                   | 2 (15.4)                                       | 0 (0.0)                                      |
| CTLA-4 inhibitor                     | 1 (6.3)                | NA                       | 1 (6.3)              | 1 (10.0)                       | 0 (0.0)                   | 1 (7.7)                                        | 0 (0.0)                                      |
| Dacarbazine or CVD                   | 12 (75.0)              | NA                       | 12 (75.0)            | 7 (70.0)                       | 5 (83.3)                  | 9 (69.2)                                       | 3 (100.0)                                    |
| Characteristic                          | All patients (N = 124) | Non-progressors (N = 14) | Resistant (N = 110) | Original resistance definitions | SITC resistance definitions |
|----------------------------------------|------------------------|--------------------------|---------------------|---------------------------------|--------------------------|
|                                        |                        |                          |                     | Primary (N=61)                  | Secondary (N=49)         |
|                                        |                        |                          |                     | Primary (N=76)                  | Secondary (N=32)         |
| Paclitaxel + carboplatin               | 1 (6.3)                | NA                       | 1 (6.3)             | 0 (0.0)                         | 1 (16.7)                |
|                                        |                        |                          |                     |                                 | 1 (7.7)                 |
|                                        |                        |                          |                     |                                 | 0 (0.0)                 |
| Site of baseline biopsy                |                        |                          |                     |                                 |                          |
| Patients with data                     | 124                    | 14                       | 110                 | 61                              | 49                       |
| Skin                                   | 56 (45.2)              | 2 (14.3)                 | 54 (49.1)           | 28 (45.9)                       | 26 (53.1)               |
|                                        |                        |                          |                     |                                 | 36 (47.4)               |
|                                        |                        |                          |                     |                                 | 16 (50.0)               |
| Lymph node                             | 24 (19.4)              | 5 (35.7)                 | 19 (17.3)           | 10 (16.4)                       | 9 (18.4)                |
|                                        |                        |                          |                     |                                 | 14 (18.4)               |
|                                        |                        |                          |                     |                                 | 5 (15.6)                |
| Mucosal surface                        | 21 (16.9)              | 3 (21.4)                 | 18 (16.4)           | 12 (19.7)                       | 6 (12.2)                |
|                                        |                        |                          |                     |                                 | 13 (17.1)               |
|                                        |                        |                          |                     |                                 | 5 (15.6)                |
| Other                                  | 23 (18.6)              | 4 (28.6)                 | 19 (17.3)           | 11 (18.0)                       | 8 (16.3)                |
|                                        |                        |                          |                     |                                 | 13 (17.1)               |
|                                        |                        |                          |                     |                                 | 6 (18.8)                |
| Site of Post-treatment biopsy          |                        |                          |                     |                                 |                          |
| Patients with data                     | NA                     | NA                       | 90                  | 53                              | 37                       |
| Skin                                   | NA                     | NA                       | 30 (33.3)           | 15 (28.3)                       | 15 (40.5)               |
|                                        |                        |                          |                     |                                 | 20 (29.4)               |
|                                        |                        |                          |                     |                                 | 9 (42.9)                |
| Lymph node                             | NA                     | NA                       | 19 (21.1)           | 12 (22.6)                       | 7 (18.9)                |
|                                        |                        |                          |                     |                                 | 16 (23.5)               |
|                                        |                        |                          |                     |                                 | 3 (14.3)                |
| Mucosal surface                        | NA                     | NA                       | 10 (11.1)           | 5 (9.4)                         | 5 (13.5)                |
|                                        |                        |                          |                     |                                 | 7 (10.3)                |
|                                        |                        |                          |                     |                                 | 3 (14.3)                |
| Other                                  | NA                     | NA                       | 31 (34.4)           | 21 (39.6)                       | 10 (27.0)               |
|                                        |                        |                          |                     |                                 | 25 (36.8)               |
|                                        |                        |                          |                     |                                 | 6 (28.6)                |

CVD, cisplatin, vinblastine and dacarbazine; ECOG, Eastern Cooperative Oncology Group; NA, not applicable; SD, standard deviation; SITC, Society for Immunotherapy of Cancer; WT, wild-type.

A All values given as n (%) unless otherwise stated.

B Only those unknown primary tumors with the clinical appearance of mucosal melanoma were included in the study.

C M0, no distant metastases; M1a, non-visceral metastases to skin, soft tissue including muscles, and/or nonregional lymph nodes; M1b, distant metastases to lung; M1c, all other visceral metastases and any distant metastases with elevated lactase dehydrogenase levels.
**Supplementary Table 2. Patient treatment and clinical outcomes**

|                                | All patients (N = 124) | Non-progressors (N = 14) | Resistant (N = 110) | Original resistance definitions | SITC resistance definitions |
|--------------------------------|-------------------------|--------------------------|---------------------|-------------------------------|-----------------------------|
|                                |                         |                          |                     | Primary                       | Secondary                   |
| **Type of anti-PD-1 treatment**|                         |                          |                     |                               |                             |
| Nivolumab                      | 20 (16.1)               | 4 (28.6)                 | 16 (14.5)           | 6 (9.8)                       | 10 (20.4)                  |
| Pembrolizumab                  | 104 (83.9)              | 10 (71.4)                | 94 (85.5)           | 55 (90.2)                     | 39 (79.6)                  |
| **Number of cycles received**  |                         |                          |                     |                               |                             |
| Median (range)                 | 10 (2–67)               | 33 (14–67)               | 8 (2–64)            | 5.0 (2–27)                    | 19.0 (5–64)                |
| **Duration of anti-PD-1 treatment (months)** |                     |                          |                     |                               |                             |
| Median (range)                 | 6.3 (1.3–45.0)          | 23.2 (9.4–38.4)          | 5.4 (1.3–45.0)      | 2.79 (1.3–18.4)               | 12.45 (3.7–45.0)           |
| **Duration of response (months)** |                     |                          |                     |                               |                             |
| Patients with data             | 94                      | 14                       | 80                  | 31                            | 49                          |
| Median (range)                 | 6.0 (0.0–44.5)          | 27.2 (15.6–44.5)         | 4.7 (0.0–40.7)      | 1.64 (0.0–2.9)                | 7.87 (3.1–40.7)            |
| **Best overall response**      |                         |                          |                     |                               |                             |
| Complete response              | 11 (8.9)                | 7 (50.0)                 | 4 (3.6)             | 1 (1.6)                       | 3 (6.1)                    |
| Partial response               | 35 (28.2)               | 7 (50.0)                 | 28 (25.5)           | 6 (9.8)                       | 22 (44.9)                  |
| Stable disease                 | 48 (38.7)               | 0 (0.0)                  | 48 (43.6)           | 24 (39.3)                     | 24 (49.0)                  |

Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer doi: 10.1136/jitc-2022-004879

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance

2022; J Immunother Cancer, et al. Shui IM
|                                | All patients (N = 124) | Non-progressors (N = 14) | Resistant (N = 110) | Original resistance definitions | SITC resistance definitions |
|--------------------------------|-------------------------|--------------------------|---------------------|--------------------------------|-----------------------------|
|                                |                         |                          |                     | Primary                        |                             |
|                                |                         |                          |                     | Secondary                       |                             |
| Progressive disease            | 30 (24.2)               | 0 (0.0)                  | 30 (27.3)           | 30 (49.2)                      | 0 (0.0)                     |
| Vital status at last follow-up |                         |                          |                     | 30 (39.5)                      | 0 (0.0)                     |
| Alive                          | 64 (51.6)               | 14 (100)                 | 50 (45.5)           | 22 (36.1)                      | 28 (57.1)                   |
| Dead                           | 60 (48.4)               | 0 (0.0)                  | 60 (54.5)           | 39 (63.9)                      | 21 (42.9)                   |

SD, standard deviation; SITC, Society for Immunotherapy of Cancer.

A All values given as n (%) unless otherwise stated.

B Date of last follow-up was used to calculate duration of therapy and response for 9 non-responders whose treatment was ongoing at the end of the study period.

C Duration of response is reported for patients with a best overall response of complete response, partial response, and stable disease. Patients with BOR of CR, PR, or SD <90 days (original definition) and <180 days (SITC definition) before progression are considered primary resistance. Patients with a BOR of ≥90 days (original definition) and ≥180 days (SITC definition) before progression are considered secondary resistance.
## Supplementary Table 3. Patient characteristics by acral and mucosal melanoma

| Characteristic                              | Acral ($N = 76$) | Mucosal/Unknown Primary ($N = 48$) |
|---------------------------------------------|------------------|-----------------------------------|
| **Age**                                     |                  |                                   |
| Mean (SD)                                   | 58.9 (12.38)     | 60.5 (12.6)                       |
| **Gender**                                  |                  |                                   |
| Female                                      | 34 (44.7)        | 23 (47.9)                         |
| Male                                        | 42 (55.3)        | 25 (52.1)                         |
| **BRAF status**                             |                  |                                   |
| Subjects with data                          | 74               | 48                                 |
| V600                                        | 11 (14.9)        | 4 (8.3)                           |
| WT                                          | 62 (83.8)        | 43 (89.6)                         |
| Other                                       | 1 (1.4)          | 1 (2.1)                           |
| **M stage at biopsy**                       |                  |                                   |
| M0                                          | 1 (1.3)          | 5 (10.4)                          |
| M1a                                         | 32 (42.1)        | 12 (25.0)                         |
| M1b                                         | 5 (6.6)          | 4 (8.3)                           |
| M1c                                         | 38 (50.0)        | 27 (56.3)                         |
| **ECOG performance status**                 |                  |                                   |
| 1                                           | 76 (100.0)       | 44 (97.9)                         |
| 2                                           | 0 (0.0)          | 1 (2.1)                           |
| **Lines of previous systemic therapy**      |                  |                                   |
| 0                                           | 64 (84.2)        | 4 (9.0)                           |
| 1                                           | 11 (14.5)        | 4 (9.1)                           |
| 2                                           | 1 (1.3)          | 0 (0.0)                           |
| **Type of previous systemic therapy**       |                  |                                   |
| Subjects with data                          | 12               | 4                                 |
| BRAF and/or MEK inhibitor                    | 1 (8.3)          | 1 (25.0)                          |
| CTLA-4 inhibitor                            | 0 (0.0)          | 1 (25.0)                          |
| Dacarbazine                                 | 10 (83.3)        | 2 (50.0)                          |
| Paclitaxel + carboplatin                    | 1 (8.3)          | 0 (0.0)                           |
| **Type of anti-PD-1 treatment**             |                  |                                   |
| Nivolumab                                   | 12 (15.8)        | 8 (16.7)                          |
Pembrolizumab

|                | 64 (84.2) | 40 (83.3) |
|----------------|-----------|-----------|
| Cycles received|           |           |
| Median (range) | 10 (2.67) | 11.5 (2.50) |
| Duration of anti-PD-1 treatment (months) |           |           |
| Median (range) | 6.29 (1.4, 45.0) | 6.67 (1.3, 26.2) |

ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; WT, wild-type.

^ All values given as n (%) unless otherwise stated.

M0, no distant metastases; M1a, non-visceral metastases to skin, soft tissue including muscles, and/or nonregional lymph nodes; M1b, distant metastases to lung; M1c, all other visceral metastases and any distant metastases with elevated lactase dehydrogenase levels.
Supplementary Table 4. Baseline and post-treatment comparisons of mRNA signature expression levels in the non-progressor and resistant groups

| mRNA signature (number of genes in consensus gene set) | Baseline expression, non-progressors versus resistant AUROC (95% CI) | Post-treatment change from baseline, resistant Effect size (95% CI) | Post-treatment change from baseline, primary versus secondary resistance AUROC (95% CI) | Original study definition | SITC definition |
|--------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|---------------------------|-----------------|
| GEP (18)                                                | 0.78 (0.62, 0.94)                                                  | 0.34 (–0.05, 0.72)                                               | 0.53 (0.37, 0.68)                                                | 0.51 (0.33, 0.68)         |                 |
| Angiogenesis (16)                                       | 0.62 (0.46, 0.78)                                                  | 0.07 (–0.31, 0.45)                                               | 0.48 (0.32, 0.64)                                                | 0.59 (0.41, 0.77)         |                 |
| Glycolysis (30)                                         | 0.59 (0.37, 0.81)                                                  | –0.12 (–0.50, 0.26)                                              | 0.51 (0.35, 0.67)                                                | 0.53 (0.35, 0.72)         |                 |
| Hypoxia (20)                                            | 0.61 (0.39, 0.83)                                                  | –0.07 (–0.45, 0.31)                                              | 0.51 (0.35, 0.67)                                                | 0.47 (0.29, 0.65)         |                 |
| gMDSC (43)                                              | 0.51 (0.31, 0.70)                                                  | –0.03 (–0.41, 0.35)                                              | 0.63 (0.48, 0.79)                                                | 0.60 (0.42, 0.78)         |                 |
| mMMDSC (218)                                            | 0.61 (0.44, 0.77)                                                  | 0.23 (–0.15, 0.61)                                               | 0.60 (0.45, 0.75)                                                | 0.61 (0.46, 0.76)         |                 |
| MYC (32)                                                | 0.56 (0.35, 0.77)                                                  | 0.23 (–0.15, 0.61)                                               | 0.61 (0.46, 0.77)                                                | 0.60 (0.42, 0.77)         |                 |
| Proliferation (227)                                     | 0.55 (0.34, 0.77)                                                  | 0.03 (–0.35, 0.41)                                               | 0.61 (0.46, 0.76)                                                | 0.55 (0.36, 0.75)         |                 |
| RAS (11)                                                | 0.49 (0.27, 0.71)                                                  | –0.09 (–0.46, 0.29)                                              | 0.57 (0.42, 0.73)                                                | 0.67 (0.51, 0.84)         |                 |
| Stroma/EMT/TGFB1 (51)                                   | 0.63 (0.45, 0.81)                                                  | –0.12 (–0.50, 0.26)                                              | 0.50 (0.34, 0.66)                                                | 0.50 (0.27, 0.63)         |                 |
| WNT (13)                                                | 0.47 (0.30, 0.64)                                                  | –0.42 (–0.81, –0.04)                                             | 0.57 (0.42, 0.73)                                                | 0.76 (0.62, 0.90)         |                 |
| IFNA1 (3)                                               | 0.48 (0.32, 0.65)                                                  | –0.50 (–0.89, –0.11)                                             | 0.57 (0.42, 0.73)                                                | 0.54 (0.36, 0.71)         |                 |
| Cytokine (12)                                           | 0.58 (0.38, 0.77)                                                  | –0.01 (–0.38, 0.37)                                              | 0.57 (0.41, 0.73)                                                | 0.62 (0.47, 0.77)         |                 |

AUROC, area under the receiver operating characteristic; CI, confidence interval; EMT, epithelial-to-mesenchymal transition; GEP, 18-gene T cell-inflamed gene expression profile (TcellinfGEP); gMDSC, granulocytic myeloid-derived suppressor cells; mMMDSC, monocytic myeloid-derived suppressor cells; SITC, Society for Immunotherapy of Cancer.

A All mRNA signatures other than GEP were adjusted for GEP values.
### Supplementary Table 5. Baseline and post-treatment comparisons of infiltrating immune cell densities in the non-progressor and resistant groups

| Cell type | Baseline expression, non-progressors versus resistant | Post-treatment change from baseline, primary versus secondary resistance |
|-----------|------------------------------------------------------|-------------------------------------------------------------------|
|           | Original study definition | SITC definition |
| CD8⁺      | 0.78 (0.65, 0.90) | 0.53 (0.39, 0.67) | 0.58 (0.43, 0.73) |
| CD11c⁺    | 0.70 (0.54, 0.87) | 0.60 (0.46, 0.75) | 0.62 (0.45, 0.78) |
| FOXP3⁺    | 0.73 (0.54, 0.87) | 0.58 (0.44, 0.71) | 0.69 (0.55, 0.83) |

SITC, Society for Immunotherapy of Cancer.

[^]: All values given as area under the receiver operating characteristic (95% confidence interval)
Supplementary Figure 1. Percent PD-L1 MEL score ≥2 at baseline

- Resistant (n=100): 32%
- Non-Progressor (n=13): 54%
- Primary resistant (n=55): 24%
- Secondary resistant (n=45): 42%
- Early secondary (n=30): 33%
- Late secondary (n=15): 60%

*Based on the original study definitions for resistance.*